Clinical trial tests combinations of immunotherapy drugs for prostate cancer


Vaccine-based immunotherapy from novel nanoparticle systems

Men with metastatic prostate cancer resistant to hormone therapy may be eligible to participate in a new clinical trial at the NIH Clinical Center.

James Gulley, M.D., Ph.D., of the Genitourinary Malignancies Branch is leading a study of combination immunotherapy for men with metastatic castration-resistant prostate cancer (mCRPC). mCRPC is disease that has spread beyond the prostate and no longer responds to hormone therapy. Patients will be treated with two, three or four different drugs that affect the immune system in different ways. BN-brachyury is a cancer vaccine that creates immune cells that recognize and kill certain types of cancer. M7824 can increase the body’s immune response and make it easier for immune cells to kill cancer cells. ALT-803 can supercharge tumor-killing immune cells and increase their numbers. Tumors can produce chemicals that make it hard for the immune system to recognize and attack them. Epacadostat blocks the production of these chemicals. Investigators want to determine the safety of different combinations of these drugs and whether the drugs can make tumors shrink.

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Summary Posted: Fri, 06/01/2018